Clinical Trials Logo

Nalbuphine clinical trials

View clinical trials related to Nalbuphine.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04030026 Completed - Clinical trials for Idiopathic Pulmonary Fibrosis

A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of Cough

CANAL
Start date: August 8, 2019
Phase: Phase 2
Study type: Interventional

To investigate the efficacy and safety of Nalbuphine ER (NAL ER) tablets in subjects diagnosed with Idiopathic Pulmonary Fibrosis (IPF) and evaluate it's treatment of cough in these patients. This is a two-treatment, 2-period crossover study. Subjects will be randomized in Treatment Period 1 to either NAL ER or matching placebo and evaluated for approximately 21 days. After completion of the first phase, subjects who received NAL ER will crossover to placebo and subjects who received placebo will crossover to NAL ER to complete Treatment Period 2.

NCT ID: NCT04018664 Completed - Opioid Abuse Clinical Trials

Oral Abuse Potential Study of Nalbuphine

Start date: May 29, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to measure the effects of a drug called nalbuphine (an opioid drug) compared with the effects of hydromorphone (an opioid drug) and placebo (contains no active drug ingredients). The amount of nalbuphine levels in the blood will also be measured and the safety of the study drugs will be evaluated. This study has 2 parts: Part A and Part B.